COYA - CIK 0001835022
The table below shows Coya Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$6.21M | -$2.83M | $2.15M | -$3.86M | -$1.98M |
| Capital expenditure | - | - | - | - | - |
| Investing cash flow | -$885.00K | - | -$25.00K | - | - |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
Coya Therapeutics, Inc. reported operating cash flow of -$10.74M for fiscal year 2025. That is down 4.4% from -$10.29M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$3.90M (FY 2021) to -$10.74M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | $11.00M | $19.14K | $1.24M | $14.25M | -$65.23K |